CGEM
Cullinan Therapeutics Inc
NASDAQ · Biotechnology
$12.23
+0.38 (+3.21%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 156.49M | 140.29M | 129.25M |
| Net Income | -25,188,754 | -25,282,384 | -20,083,076 |
| EPS | — | — | — |
| Profit Margin | -16.1% | -18.0% | -15.5% |
| Rev Growth | +6.1% | +12.8% | -3.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 34.83M | 35.06M | 41.53M |
| Total Equity | 464.14M | 436.45M | 409.65M |
| D/E Ratio | 0.08 | 0.08 | 0.10 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -32,256,643 | -27,830,603 | -25,262,091 |
| Free Cash Flow | -9,992,952 | -10,952,071 | -13,180,515 |